The Europe Liver Disease Therapeutic Market is expected to grow from US$ 4.34 billion in 2024 to US$ 8.29 billion by 2033, at a CAGR of 7.44% from 2025 to 2033. The rising incidence of liver-related diseases, development in therapeutic treatments, and an increase in awareness about liver health are major drivers for the market's sustained growth in the healthcare industry of Europe.
Rising aging population and the rise of non-alcoholic fatty liver disease (NAFLD) have further driven demand for advanced and efficient therapies. Governmental institutions and healthcare organizations in Europe are actively encouraging early diagnosis and timely treatment, thus driving the uptake of liver disease therapeutics. Additionally, pharma innovations and clinical trials keep accelerating therapy effects, rendering these therapies more accessible and effective. Liver disease therapeutics, therefore, have high importance and stable growth in Europe's healthcare.
Europe Liver Disease Therapeutic Market Overview
Liver disease treatments involve a variety of medications used to treat, cure, or control diverse liver ailments including hepatitis, cirrhosis, fatty liver, and liver cancer. They range from antiviral medications, corticosteroids, immunosuppressants, and antifibrotic drugs to liver transplantation in serious conditions. In Europe, the occurrence of liver conditions has increased tremendously based on lifestyle such as alcohol use, obesity, and viral infections like Hepatitis B and C.Rising aging population and the rise of non-alcoholic fatty liver disease (NAFLD) have further driven demand for advanced and efficient therapies. Governmental institutions and healthcare organizations in Europe are actively encouraging early diagnosis and timely treatment, thus driving the uptake of liver disease therapeutics. Additionally, pharma innovations and clinical trials keep accelerating therapy effects, rendering these therapies more accessible and effective. Liver disease therapeutics, therefore, have high importance and stable growth in Europe's healthcare.
Growth Drivers in Europe Liver Disease Therapeutic Market
Increasing Incidence of Liver Diseases
Europe is among the leading markets for liver disease therapy drugs, fueled by staggering figures that show liver cirrhosis alone is responsible for as many as 170,000 deaths every year on the continent. The increasing incidence of liver conditions-from fatty liver disease to cirrhosis and hepatitis-acts as a strong driver of expansion for the European liver disease therapy market. This concerning development is further fueled by lifestyle factors, such as rising obesity rates, growing alcohol consumption, and the transmission of viral infections, that all contribute to compromised liver health. Governments and healthcare institutions, in turn, are increasing their emphasis on early detection and quality treatment, thus driving demand for novel and advanced therapeutic interventions across the region.Advancements in Therapeutic Solutions
Recent advances in medical research and pharmaceutical development have brought with them a new dawn of more effective and more secure treatments for liver disease, greatly improving the care of patients. Advances in antiviral drugs, the fast-emerging area of immunotherapy, and improvements in regenerative medicine - most notably through new stem cell therapeutic techniques - are bringing about revolutionary gains in patient outcomes. These advances are not only fostering improved health but driving the incorporation of liver disease therapeutics into Europe's healthcare systems, thus driving the growth of the market. In a remarkable development, the European Commission approved conditional in October 2024 Iqirvo (elafibranor) 80mg tablets for the specific treatment of primary biliary cholangitis (PBC). This is to be administered in combination with ursodeoxycholic acid (UDCA) and represents hope for better management of this difficult disease and highlights the continued advancements in liver disease treatments.Supportive Government Initiatives
Governments in Europe are proactively implementing extensive health programs focused on decreasing liver disease-related mortality rates considerably. All such programs place significant value on early diagnosis and timely intervention, indicating a strong resolve to enhance public health. In support of these programs, more funding has been devoted to research, publicity campaigns, and healthcare infrastructure upgrades, making more effective therapeutic options easily accessible. These forward-looking steps are proving to be a vital part of developing a strong growth path for the therapeutic market for liver disease in the continent. In February 2024, a groundbreaking research project at the Hanover Medical School (MHH) in the departments of Hepatology, Infectiology, and Endocrinology will venture into the promising future of RNA as a new therapy option for liver diseases. This pioneering study aims to explore particular RNA structures that can be exploited as therapeutic targets to manage the course of liver fibrosis and Metabolic Associated Steatotic Hepatitis (MASH). The ambitious initiative has received significant funding from the Boehringer Ingelheim Foundation, which is committing around £500,000 over three years under its Rise Up! program, aimed at promoting cutting-edge basic research in medicine.Issues in the Therapeutic Market for Liver Disease in Europe
Exorbitant Costs of Treatment
The economic burdens brought about by sophisticated treatments for liver disease, including a variety of therapies like antiviral drugs, cutting-edge immunotherapies, and intricate liver transplantation procedures, are significantly high. These exorbitant expenses can cause a huge strain on healthcare systems, generally limiting access for patients, particularly in countries with limited healthcare funding. This financial burden may dampen market expansion, especially in areas where insurance coverage is low or government assistance is not available, leading to a cycle where most people do not have access to the critical care they require.Limited Awareness and Late Diagnosis
Various liver diseases tend to advance quietly, with few to no symptoms until they are advanced. This is the factor responsible for a delay in both diagnosis and treatment, hence making patient outcomes complicated. Despite numerous campaigns for raising awareness at the public and professional levels, the numbers of early detection cases in many parts of Europe are still unacceptably low. This is a recurring problem that greatly hampers the efficacy of therapeutic interventions since dealing with advanced liver disease is more complicated, lengthy, and costly. Therefore, this kind of situation also inhibits the development of the market, restraining potential for innovation and enhancement in managing the liver's health.Europe Liver Disease Chemotherapy Drugs Market
Europe's liver disease chemotherapy drugs market is pivotal, particularly in the treatment of hepatocellular carcinoma, the most prevalent liver cancer. Chemotherapy is a common treatment choice where surgery is not possible. Research initiatives are improving the safety and efficacy profiles of these drugs, which in turn increase survival rates and fuel demand in the oncology treatment arenas in Europe.Europe Liver Disease Therapeutic Vaccines Market
Therapeutic vaccines for liver diseases, including viral hepatitis, are an emerging market in Europe's medical industry. These vaccines help enhance the immune system to contain or eliminate diseases such as Hepatitis B and C. Enhanced R&D spending and government health programs to fight viral liver infection have fueled the use of therapeutic vaccines, driving consistent growth in the market.Europe Liver Disease Therapeutic Viral Hepatitis Market
Viral hepatitis, particularly Hepatitis B and C, remains a prominent health issue throughout Europe. The antiviral therapy market is growing as governments and healthcare professionals step up their efforts to eradicate viral hepatitis through screening, vaccination, and high-tech therapeutics. Pharmaceutical innovation and publicity campaigns are fueling increased use of treatment measures in this market sector.Europe Alcoholic Liver Disease Market
Alcoholic liver disease persists in Europe through social and cultural patterns associated with alcohol use. The need for proper treatments, such as medications, lifestyle management programs, and liver transplantation, increases every year. Governments and healthcare practitioners are more and more interested in managing this public health concern, contributing to the demand for specific therapies in the alcoholic liver disease market.Europe Liver Disease Therapeutic Hospitals Market
European hospitals play a crucial role in delivering expert care for liver disease sufferers by providing a variety of diagnostic, surgical, and treatment services. Upgrades in hospital facilities, such as the availability of leading-edge treatment technologies and well-trained doctors and specialists, fuel this market segment's growth. Growing hospital admissions for liver disorders also increase market demand.France Liver Disease Therapeutic Market
France's liver disease therapeutic market is supported by a well-developed healthcare system and proactive government efforts with respect to liver health. France's healthcare professionals are engaged actively in research and early diagnosis initiatives, especially with respect to hepatitis and cirrhosis. Strong public health awareness and availability of novel therapies make France an important contributor in Europe's overall liver disease therapeutic market.United Kingdom Liver Disease Therapeutic Market
The therapeutic market for liver disease in the United Kingdom is growing as a result of increased incidence of non-alcoholic fatty liver disease and alcoholic liver disease. NHS programs and public health campaigns focus on increasing diagnosis and treatment availability. Moreover, intense pharmaceutical R&D efforts and technological progress in the management of liver disease underlie the market's consistent growth in the UK healthcare environment.Netherlands Liver Disease Therapeutic Market
The Netherlands is experiencing consistent growth in its liver disease therapeutic market, fueled by sophisticated healthcare systems and public health initiatives for liver health. Hepatitis incidence reduction and early detection of liver disorders are major drivers. Improved standards of healthcare and advancements in medical care also drive market growth in this country.Russia Liver Disease Therapeutic Market
Russia's therapeutics market for liver disease is expanding owing to a very high incidence of hepatitis infections and lifestyle disorders affecting the liver. Still, rural healthcare access challenges persist. Government efforts to increase screening and treatment and invest in healthcare infrastructure are slowly enhancing the situation. The demand for sophisticated liver therapeutics is still increasing in urban regions.Market Segmentation
Therapy Type
- Anti-Rejection Drugs/Immunosuppressants
- Chemotherapy Drugs
- Targeted therapy
- Vaccines
- Immunoglobulins
- Corticosteroids
- Anti-Viral Drugs
Disease Type
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Viral Hepatitis (B, C, D)
- Alcoholic Liver Disease (ALD)
- Autoimmune Liver Disease (ALD)
End Users
- Hospitals
- Laboratories
- Others
Country
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- Netherlands
- Russia
- Poland
- Greece
- Norway
- Romania
- Portugal
- Rest of Europe
Key Players Analysis (Overviews, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis)
- Abbott Laboratories
- Astellas Pharma Inc.
- Bristol-Mayers Squibb
- Gilead Sciences
- GlaxoSmithKline Pharmaceuticals Ltd
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceuticals
Table of Contents
1. Introduction3. Executive Summary11. Value Chain Analysis
2. Research & Methodology
4. Market Dynamics
5. Europe Liver Disease Therapeutic Market
6. Market Share Analysis
7. Therapy Type
8. Disease Type
9. End Users
10. Country
12. Porter's Five Forces Analysis
13. SWOT Analysis
14. Market Outlook and Opportunities
15. Pricing Benchmark Analysis
16. Key Players Analysis
Companies Mentioned
The major companies profiled in this Europe Liver Disease Therapeutic market report include:- Abbott Laboratories
- Astellas Pharma Inc.
- Bristol-Mayers Squibb
- Gilead Sciences
- GlaxoSmithKline Pharmaceuticals Ltd
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceuticals
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | July 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 4.34 Billion |
| Forecasted Market Value ( USD | $ 8.29 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 12 |
